Fulvestrant - Ready to start its journey in the breast cancer adjuvant endocrine world?

European Journal of Cancer

Volumn 41, Issue 3, 2005, Pages 341-343

  Piccart Gebhart, M J ^a   Loi, S M ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; MITOGEN ACTIVATED PROTEIN KINASE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL STRAIN MCF 7; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GENE EXPRESSION; GENE OVEREXPRESSION; HORMONE RELEASE; HUMAN; METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZATION; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME;

EID: 13244299339     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.09.019     Document Type: Editorial

References (25)

1. C.K. Osborne, A. Wakeling, and R.I. Nicholson Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action Br J Cancer 90 Suppl 1 2004 S2 S6
2. A. Howell, D. DeFriend, J. Robertson, R. Blamey, and P. Walton Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer Lancet 345 8941 1995 29 30
3. X.F. Hu, M. Veroni, M. De Luise, A. Wakeling, R. Sutherland, and C.K. Watts Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182,780 Int J Cancer 55 5 1993 873 876
4. A. Howell, J.F. Robertson, J. Quaresma Albano, A. Aschermannova, L. Mauriac, and U.R. Kleeberg Fulvestrant, formerlyICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 16 2002 3396 3403
5. C.K. Osborne, J. Pippen, S.E. Jones, L.M. Parker, M. Ellis, and S. Come Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 16 2002 3386 3395
6. Robertson JF, Come S, Jones SE, Beex M, Kaufman M, Makris A, et al. Endocrine treatment options for advanced breast cancer - the role of fulvestrant. Eur J Cancer 2005, this issue (doi: 10.1016/j.ejca.2004.07.035)
7. A. Howell, J.F. Robertson, P. Abram, M.R. Lichinitser, R. Elledge, and E. Bajetta Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 9 2004 1605 1613
8. A.E. Wakeling, and J. Bowler Steroidal pure antioestrogens J Endocrinol 112 3 1987 R7 R10
9. C.K. Osborne, E.B. Coronado-Heinsohn, S.G. Hilsenbeck, B.L. McCue, A.E. Wakeling, and R.A. McClelland Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer J Natl Cancer Inst 87 10 1995 746 750
10. J. Frasor, F. Stossi, J.M. Danes, B. Komm, C.R. Lyttle, and B.S. Katzenellenbogen Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells Cancer Res 64 4 2004 1522 1533
11. H. Mouridsen, M. Gershanovich, Y. Sun, R. Perez-Carrion, C. Boni, and A. Monnier Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 10 2001 2596 2606
12. J.M. Nabholtz, J. Bonneterre, A. Buzdar, J.F. Robertson, and B. Thurlimann Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results Eur J Cancer 39 12 2003 1684 1689
13. R.A. Betensky, D.N. Louis, and J.G. Cairncross Influence of unrecognized molecular heterogeneity on randomized clinical trials J Clin Oncol 20 10 2002 2495 2499
14. T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, and H. Johnsen Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 2001 10869 10874
15. C. Sotiriou, S.Y. Neo, L.M. McShane, E.L. Korn, P.M. Long, and A. Jazaeri Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci USA 100 18 2003 10393 10398
16. X.J. Ma, Z. Wang, P. Ryan, S.J. Isakoff, A. Barmettler, and A. Fuller A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen Cancer Cell 5 2004 607 616
17. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients-NSABP 20 and B-14. In: 26th San Antonio Breast Cancer Symposium 2003, December 2003 (abstr 16), 2003
18. Jansen M, Foekens J, Van Staveren I, Dirkwager-Keil M, Look M, Meijers-Van Gelder M, et al. Molecular classificaiton of tamoxifen-responsive and resistant breast carcinomas by gene expression profiling. In: San Antonio Breast Cancer Symposium 2003, San Antonio, TX, December 2003, Abstract 26, 2003
19. S. Gruvberger, M. Ringner, Y. Chen, S. Panavally, L.H. Saal, and A. Borg Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns Cancer Res 61 16 2001 5979 5984
20. S.R. Johnston, J. Head, S. Pancholi, S. Detre, L.A. Martin, and I.E. Smith Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer Clin Cancer Res 9 1 Pt 2 2003 524S 532S
21. R. Schiff, S. Massarweh, J. Shou, and C.K. Osborne Breast cancer endocrine resistance: how growth factor signaling and oestrogen receptor coregulators modulate response Clin Cancer Res 9 1 Pt 2 2003 447S 454S
22. A.E. Wakeling, R.I. Nicholson, and J.M. Gee Prospects for combining hormonal and nonhormonal growth factor inhibition Clin Cancer Res 7 12 Suppl 2001 4350s 4355s discussion 4411s-12s
23. S. Okubo, J. Kurebayashi, T. Otsuki, Y. Yamamoto, K. Tanaka, and H. Sonoo Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells Br J Cancer 90 1 2004 236 244
24. P.E. Goss, J.N. Ingle, S. Martino, N.J. Robert, H.B. Muss, and M.J. Piccart A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer New Engl J Med 349 19 2003 1793 1802
25. R.C. Coombes, E. Hall, L.J. Gibson, R. Paridaens, J. Jassem, and T. Delozier A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer New Engl J Med 350 11 2004 1081 1092